 |
 |
Date Announced: 06 Jun 2012
Performed with the IQ 577™ Laser and EndoProbe® Instrumentation.
MOUNTAIN VIEW, Calif., June 6, 2012 /PRNewswire/ -- IRIDEX Corporation (IRIX) today announced the use of MicroPulse™ Laser Therapy (MPLT), using the IQ 577 laser coupled with EndoProbe® instrumentation, that was successfully performed by Sam Mansour, MD, Medical Director of the Virginia Retina Center and Clinical Professor of Ophthalmology at The George Washington University School of Medicine & Health Sciences. This is the first time tissue-sparing laser therapy has been delivered through an intraocular fiber-optic probe in a surgical setting.
Dr. Mansour explains, "Endo-MicroPulse laser surgery is a much more direct and controlled method than slit lamp delivery, which gives me the flexibility to treat my most difficult cases without compromising the retinal tissue."
The groundbreaking surgery was performed with the IQ 577 laser – the first visible wavelength laser to offer MicroPulse technology. "Endo-MicroPulse is effective in cases of very thin retinas due to its ability to preserve tissue rather than destroy it with conventional laser therapy," commented Dr. Mansour.
Dominik Beck, Ph.D., President and Chief Executive Officer of IRIDEX, said, "Expanding MPLT applications from physicians' offices into the operating room and surgery centers will continue to drive growth in our laser systems as well as open up opportunities to expand the breadth of our consumables portfolio. IRIDEX continues to be committed to the development and commercialization of new treatments for sight-threatening diseases."
Source: Iridex
E-mail: via web site
Web Site: www.iridex.com
| © 2024 SPIE Europe |
|
